Treatment of dementia in Parkinson’s disease

Jennifer G Goldman*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


Dementia is a frequent and debilitating complication of Parkinson’s disease (PD). It typically is gradual in onset and occurs after a number of years of disease. Longitudinal studies indicate that up to 80% of PD patients may develop dementia during their disease course, though this figure varies. Cognitive deficits in PD dementia (PDD) affect more than one cognitive domain, such as attention, working memory, executive function, memory, language, and/or visuospatial functions and are severe enough to impair daily life, independent of motor symptoms. Behavioral symptoms such as depression, apathy, psychosis, and excessive daytime sleepiness can accompany PDD. To date, rivastigmine is the only FDA-approved medication for PDD. There is growing interest in other pharmacological and non-pharmacological treatments for PDD including medications, neuromodulation, and physical and cognitive exercise. Management strategies include avoiding medications that can exacerbate cognitive impairment (such as anticholinergics); treating comorbid neuropsychiatric symptoms; addressing driving, safety, and/or work issues; and providing support to the patient and care partner.

Original languageEnglish (US)
Title of host publicationCurrent Clinical Neurology
PublisherHumana Press Inc
Number of pages4
StatePublished - Jan 1 2019

Publication series

NameCurrent Clinical Neurology
ISSN (Print)1559-0585


  • Cholinesterase inhibitors
  • Dementia
  • Executive function
  • Memory
  • Mild cognitive impairment
  • Psychosis

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Treatment of dementia in Parkinson’s disease'. Together they form a unique fingerprint.

Cite this